A Microdose Study to Evaluate the Biodistribution of [11C]-GSK2256098 in the Lungs and Heart of Healthy Subjects and Idiopathic Pulmonary Arterial Hypertension (PAH) Patients Using Positron Emission Tomography (PET)
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs GSK 2256098 (Primary)
- Indications Pulmonary arterial hypertension
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 25 Aug 2017 Status changed from recruiting to completed.
- 20 Mar 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jul 2017.
- 10 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Jul 2017.